You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

 

Online download statistics by month:

Online download statistics by month: June 2020 to September 2025

AbstractFullPdf
Jun 202018318343
Jul 202039739782
Aug 202013213042
Sep 202014314339
Oct 2020969638
Nov 202011811544
Dec 202012812814
Jan 2021979743
Feb 202112512526
Mar 202112512530
Apr 2021878728
May 2021909031
Jun 202110110149
Jul 2021999960
Aug 2021575749
Sep 202111411461
Oct 2021868681
Nov 2021888768
Dec 2021788140
Jan 2022969734
Feb 2022565722
Mar 2022888848
Apr 2022828941
May 2022808732
Jun 202211111834
Jul 202210010736
Aug 2022748035
Sep 2022748341
Oct 2022657126
Nov 2022626434
Dec 2022515118
Jan 2023505031
Feb 2023727224
Mar 2023646639
Apr 2023515224
May 2023333520
Jun 202317517518
Jul 2023727231
Aug 2023515222
Sep 2023424230
Oct 2023424214
Nov 2023464617
Dec 2023696932
Jan 202415815939
Feb 2024606035
Mar 202416416434
Apr 202414814945
May 2024848521
Jun 202416716739
Jul 2024707121
Aug 2024767727
Sep 2024505023
Oct 2024939440
Nov 2024727338
Dec 2024989941
Jan 202511111147
Feb 202526026050
Mar 2025848439
Apr 202512812942
May 2025535430
Jun 2025404522
Jul 2025220
Sep 2025110
Total596960402204